Eli Lilly & Company (NYSE:LLY) Lilly Corporate Center Indianapolis, IN 46285 Phone: (317) 276-2000 Fax: (317) 276-4878 http://www.lilly.com
Eli Lilly and Company was incorporated in 1901 in Indiana to succeed to the drug manufacturing business founded in Indianapolis, Indiana, in 1876 by Colonel Eli Lilly. The Company discovers, develops, manufactures, and sells products in one significant business segment, pharmaceutical products. It also has an animal health business segment. The Company's products include: Neurosciences products including; Zyprexa(r), for the treatment of schizophrenia, acute mixed or manic episodes associated with bipolar I disorder, and bipolar maintenance; Cymbalta(r), for the treatment of major depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, and in the United States for the management of fibromyalgia; Strattera(r), for the treatment of attention-deficit hyperactivity disorder in children, adolescents and adults; Prozac(r), for the treatment of major depressive disorder, obsessive-compulsive disorder, bulimia nervosa and panic disorder; Symbyax(r), for the treatment of bipolar depression: Endocrinology products including; Humalog(r) , Humalog Mix 75/25(r), and Humalog Mix 50/50tm, for the treatment of diabetes; Humulin(r), for the treatment of diabetes; Byetta(r), for the treatment of type 2 diabetes; Actos(r), for the treatment of type 2 diabetes; Evista(r), for the prevention and treatment of osteoporosis in postmenopausal women and for the reduction of the risk of invasive breast cancer; Forteo(r), for the treatment of osteoporosis in postmenopausal women and men at high risk for fracture; Humatrope(r), for the treatment of human growth hormone deficiency and idiopathic short stature: Oncology products, including Gemzar(r), for the treatment of pancreatic cancer; Alimta(r), for the first-line treatment, in combination with another agent, of non-small cell lung cancer for patients with non-squamous histology; for the second-line treatment of non-small cell lung cancer; Erbitu(r) is indicated both as a single agent and with other chemotherapy agents for the treatment of certain types of colorectal cancers and as a single agent or in combination with radiation therapy for head and neck cancers: Cardiovascular products, including Cialis(r), for the treatment of erectile dysfunction; Efient(r), for the prevention of atherothrombotic events in patients with acute coronary syndromes undergoing percutaneous coronary invention; ReoPro(r), for use as an adjunct to percutaneous coronary intervention, including patients undergoing angioplasty, atherectomy or stent placement; Xigris(r), for the treatment of adults with severe sepsis at high risk of death: Animal health products, including Rumensin(r), a cattle feed additive that improves feed efficiency and growth and also controls and prevents coccidiosis; Tylan(r), an antibiotic used to control certain diseases in cattle, swine, and poultry; Micotil(r), Pulmotil(r), and Pulmotil AC(r), antibiotics used to treat respiratory disease in cattle, swine, and poultry, respectively; Paylean(r) and Optaflexx(r), leanness and performance enhancers for swine and cattle, respectively; Posilac(r), a protein supplement to improve milk productivity in dairy cows; Coban(r), Monteban(r), and Maxiban(r), anticoccidial agents for use in poultry; Apralan(r), an antibiotic used to control enteric infections in calves and swine; Surmax(r), a performance enhancer for swine and poultry; Elector(r), a parasiticide for use on cattle and premises; Two products for dogs: Comfortistm, the first FDA-approved, chewable tablet that kills fleas and prevents flea infestations on dogs; and Reconciletm, for treatment of canine separation anxiety in conjunction with behavior modification training. It distributes its products through wholesale distributors and sales representatives. The Company's products compete with products manufactured by many other companies in competitive markets throughout the world. The operations are regulated by national, state and local agencies.
BUYandHOLD does not offer or provide any investment advice
or opinion regarding the nature, potential, value, suitability
or profitability of any particular security, portfolio of
securities, transaction or investment strategy. Any investment
decisions you make will be based solely on your evaluation
of your financial circumstances, investment objectives, risk
tolerance, and liquidity needs. The security and information
listed above and is being provided for informational purposes
only and should not be regarded as an offer to sell or as
a solicitation of an offer to buy and past performance is
no guarantee of future results.
The BUYandHOLD
website contains links to third-party websites on the Internet.
BUYandHOLD provides these links to these websites only as
a convenience to users of the website. Links on the BUYandHOLD
website are not endorsements by BUYandHOLD or Freedom Investments,
implied or express, of the linked sites or any products, services
or links in such sites; and no information in such sites has
been endorsed or approved by BUYandHOLD. Linked sites are
not under the control of BUYandHOLD or Freedom Investments,
and we are not responsible for the contents of any linked
site or any link contained in a linked site. No information
contained in the BUYandHOLD website or accessed through any
linked site, or any link contained in a linked site, constitutes
a recommendation by BUYandHOLD or Freedom Investments to buy,
sell or hold any security, financial product or instrument.
Information accessed through linked sites is not, nor should
be construed as, an offer or a solicitation of an offer, to
buy or sell securities by BUYandHOLD or Freedom Investments.
BUYandHOLD does not offer or provide any investment advice
or opinion regarding the nature, potential, value, suitability
or profitability of any particular security, portfolio of
securities, transaction or investment strategy, and any investment
decisions you make will be based solely on your evaluation
of your financial circumstances, investment objectives, risk
tolerance, and liquidity needs.
